ArticleCureus2026
Empty Follicle Syndrome Due to Failure of Gonadotropin-Releasing Hormone Agonist Trigger: A Retrospective Study of Possible Factors That Affect the Outcome of a Rescue Human Chorionic Gonadotropin Protocol.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Empty follicle syndrome (EFS) may occur in in vitro fertilization (IVF) cycles that use a gonadotropin-releasing hormone (GnRH) antagonist protocol with a single GnRH agonist trigger. We evaluated whether a rescue human chorionic gonadotropin (hCG) trigger can salvage oocyte retrieval in these cases, and identified factors associated with obtaining a transferable embryo. Methods Among 4,778 cycles triggered with a GnRH agonist alone between June 2014 and February 2019, we retrospectively identified 43 cycles, in 43 patients, in which no mature oocyte was obtained at the initial retrieval, and a rescue hCG protocol with repeat ovum pick-up was performed. Cycles were divided into an embryo-transfer (ET)-positive group, in which a transferable embryo was obtained (n = 30), and an ET-negative group (n = 13). Baseline and peri-trigger hormone levels were compared, and thresholds for baseline luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were derived by receiver operating characteristic analysis and evaluated in contingency tables. Results The incidence of GnRH agonist trigger failure was 0.9% (43/4,778 cycles). Oocytes were collected in 37 of 43 cycles, and a transferable embryo was obtained in 30 (69.8%); frozen-thawed transfer resulted in 18 live births, a live birth rate of 41.9% per rescue cycle. A baseline LH threshold of 1.9 mIU/mL (area under the curve (AUC) 0.83) and a baseline FSH threshold of 5.4 mIU/mL (AUC 0.85) distinguished the two groups (P < 0.001 for both); the corresponding odds of failing to obtain a transferable embryo were 33.0 (95% CI 3.7-296) and 60.0 (95% CI 6.3-572), with confidence intervals reflecting the small number of events. All 43 patients developed ovarian hyperstimulation syndrome (OHSS): 28 mild and 15 moderate. No severe OHSS requiring hospitalization occurred. Conclusions A rescue hCG trigger is a workable management strategy for EFS following a GnRH agonist trigger, yielding live births in cycles that would otherwise have been cancelled. All patients in this series developed mild or moderate OHSS, and none developed severe OHSS, although with 43 cycles the series is too small to establish the risk of severe OHSS. Baseline LH and FSH, together with the change in estradiol and progesterone between the first and second triggers, may help estimate the probability of obtaining a transferable embryo, but these thresholds are exploratory and require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.